Prediction of binding affinity and efficacy of thyroid hormone receptor ligands using QSAR and structure-based modeling methods.

The thyroid hormone receptor (THR) is an important member of the nuclear receptor family that can be activated by endocrine disrupting chemicals (EDC). Quantitative Structure-Activity Relationship (QSAR) models have been developed to facilitate the prioritization of THR-mediated EDC for the experimental validation. The largest database of binding affinities available at the time of the study for ligand binding domain (LBD) of THRβ was assembled to generate both continuous and classification QSAR models with an external accuracy of R(2)=0.55 and CCR=0.76, respectively. In addition, for the first time a QSAR model was developed to predict binding affinities of antagonists inhibiting the interaction of coactivators with the AF-2 domain of THRβ (R(2)=0.70). Furthermore, molecular docking studies were performed for a set of THRβ ligands (57 agonists and 15 antagonists of LBD, 210 antagonists of the AF-2 domain, supplemented by putative decoys/non-binders) using several THRβ structures retrieved from the Protein Data Bank. We found that two agonist-bound THRβ conformations could effectively discriminate their corresponding ligands from presumed non-binders. Moreover, one of the agonist conformations could discriminate agonists from antagonists. Finally, we have conducted virtual screening of a chemical library compiled by the EPA as part of the Tox21 program to identify potential THRβ-mediated EDCs using both QSAR models and docking. We concluded that the library is unlikely to have any EDC that would bind to the THRβ. Models developed in this study can be employed either to identify environmental chemicals interacting with the THR or, conversely, to eliminate the THR-mediated mechanism of action for chemicals of concern.

[1]  Yi-lin Li,et al.  Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone. , 2002, Journal of medicinal chemistry.

[2]  Gerta Rücker,et al.  y-Randomization and Its Variants in QSPR/QSAR , 2007, J. Chem. Inf. Model..

[3]  Huanxiang Liu,et al.  3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta. , 2008, Journal of molecular graphics & modelling.

[4]  Thomas M. Mavromoustakos,et al.  Molecular Docking and 3D-QSAR CoMFA Studies on Indole Inhibitors of GIIA Secreted Phospholipase A2 , 2010, J. Chem. Inf. Model..

[5]  G. Williams,et al.  Cloning and Characterization of Two Novel Thyroid Hormone Receptor β Isoforms , 2000, Molecular and Cellular Biology.

[6]  Markus A. Lill,et al.  Simulating α/β Selectivity at the Human Thyroid Hormone Receptor: Consensus Scoring Using Multidimensional QSAR , 2007 .

[7]  Peter Cornelius,et al.  Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics. , 2003, Bioorganic & medicinal chemistry letters.

[8]  Linda S Birnbaum,et al.  Cancer and developmental exposure to endocrine disruptors. , 2002, Environmental health perspectives.

[9]  Alexander Tropsha,et al.  Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.

[10]  R. Fletterick,et al.  A High-Throughput Screening Method to Identify Small Molecule Inhibitors of Thyroid Hormone Receptor Coactivator Binding , 2006, Science's STKE.

[11]  L. Ye,et al.  Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. , 2003, Journal of medicinal chemistry.

[12]  D. Forrest,et al.  Functions of thyroid hormone receptors in mice. , 2000, Thyroid : official journal of the American Thyroid Association.

[13]  J. Dearden,et al.  How not to develop a quantitative structure–activity or structure–property relationship (QSAR/QSPR) , 2009, SAR and QSAR in environmental research.

[14]  Johan Malm,et al.  Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta. , 2004, Bioorganic & medicinal chemistry letters.

[15]  A. Soto,et al.  Bisphenol A: Perinatal exposure and body weight , 2009, Molecular and Cellular Endocrinology.

[16]  I. Pajeva,et al.  Recent advances in the molecular modeling of estrogen receptor-mediated toxicity. , 2011, Advances in protein chemistry and structural biology.

[17]  R. Fletterick,et al.  Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor. , 2007, Molecular endocrinology.

[18]  Ivan Rusyn,et al.  Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches. , 2013, Toxicology and applied pharmacology.

[19]  C. Austin,et al.  Improving the Human Hazard Characterization of Chemicals: A Tox21 Update , 2013, Environmental health perspectives.

[20]  Ruben Abagyan,et al.  Nuclear hormone receptor targeted virtual screening. , 2003, Journal of medicinal chemistry.

[21]  Grazia Chiellini,et al.  Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[23]  Prediction of binding affinities to beta1 isoform of human thyroid hormone receptor by genetic algorithm and projection pursuit regression. , 2007, Bioorganic & medicinal chemistry letters.

[24]  Anatoly G Artemenko,et al.  Interpretation of QSAR Models Based on Random Forest Methods , 2011, Molecular informatics.

[25]  A new class of high affinity thyromimetics containing a phenyl-naphthylene core. , 2005, Bioorganic & medicinal chemistry letters.

[26]  Peter Brandt,et al.  Thyroid receptor ligands. 6. A high affinity "direct antagonist" selective for the thyroid hormone receptor. , 2006, Journal of medicinal chemistry.

[27]  Raj Kumar,et al.  The structure of the nuclear hormone receptors , 1999, Steroids.

[28]  R. Fletterick,et al.  Discovery of Small Molecule Inhibitors of the Interaction of the Thyroid Hormone Receptor with Transcriptional Coregulators* , 2005, Journal of Biological Chemistry.

[29]  Minsheng Zhang,et al.  Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141. , 2007, Bioorganic & medicinal chemistry letters.

[30]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[31]  R. Fletterick,et al.  Mechanisms of thyroid hormone action: insights from X-ray crystallographic and functional studies. , 1998, Recent progress in hormone research.

[32]  R. Fletterick,et al.  Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. , 2007, Journal of medicinal chemistry.

[33]  C. Mariash,et al.  Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs? , 2012, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[34]  V. Setola,et al.  Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. , 2009, Journal of medicinal chemistry.

[35]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[36]  Johan Malm,et al.  Thyroid receptor ligands. Part 4: 4'-amido bioisosteric ligands selective for the thyroid hormone receptor beta. , 2006, Bioorganic & medicinal chemistry letters.

[37]  라발 사우린케이.,et al.  Thyroid receptor ligands , 2009 .

[38]  R. Evans,et al.  A transcriptional co-repressor that interacts with nuclear hormone receptors , 1995, Nature.

[39]  J. Baxter,et al.  Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine. , 2004, Endocrinology.

[40]  K. Main,et al.  Thyroid effects of endocrine disrupting chemicals , 2012, Molecular and Cellular Endocrinology.

[41]  Ruili Huang,et al.  Methylsulfonylnitrobenzoates, a New Class of Irreversible Inhibitors of the Interaction of the Thyroid Hormone Receptor and Its Obligate Coactivators That Functionally Antagonizes Thyroid Hormone* , 2011, The Journal of Biological Chemistry.

[42]  Igor Polikarpov,et al.  2D QSAR studies on thyroid hormone receptor ligands. , 2007, Bioorganic & medicinal chemistry.

[43]  Johan Malm,et al.  Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor beta. , 2006, Bioorganic & medicinal chemistry letters.

[44]  V. Yong,et al.  Review: Endocrine disrupting chemicals and immune responses: a focus on bisphenol-A and its potential mechanisms. , 2013, Molecular immunology.

[45]  Martin Stahl,et al.  Binding site characteristics in structure-based virtual screening: evaluation of current docking tools , 2003, Journal of molecular modeling.

[46]  Alexander Golbraikh,et al.  Integrative chemical-biological read-across approach for chemical hazard classification. , 2013, Chemical research in toxicology.

[47]  I. Rusyn,et al.  Use of in Vitro HTS-Derived Concentration–Response Data as Biological Descriptors Improves the Accuracy of QSAR Models of in Vivo Toxicity , 2010, Environmental health perspectives.

[48]  Paola Gramatica,et al.  QSAR study of selective ligands for the thyroid hormone receptor beta. , 2007, Bioorganic & medicinal chemistry.

[49]  S. Izumo,et al.  Thyroid hormone receptor α isoforms generated by alternative splicing differentially activate myosin HC gene transcription , 1988, Nature.

[50]  Thyroid receptor ligands. Part 7: Indirect antagonists of the thyroid hormone receptor with improved affinity. , 2007, Bioorganic & medicinal chemistry letters.

[51]  G. Williams,et al.  Mechanism of thyroid hormone action. , 2002, Thyroid : official journal of the American Thyroid Association.

[52]  S. Refetoff,et al.  Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-beta gene. , 1992, The Journal of clinical endocrinology and metabolism.

[53]  Michael M. Mysinger,et al.  Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.

[54]  Alexander Tropsha,et al.  Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..

[55]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[56]  R. Guy,et al.  Synthesis and evaluation of methylsulfonylnitrobenzamides (MSNBAs) as inhibitors of the thyroid hormone receptor-coactivator interaction. , 2013, Bioorganic & medicinal chemistry letters.

[57]  R. Guy,et al.  Synthesis and evaluation of sulfonylnitrophenylthiazoles (SNPTs) as thyroid hormone receptor-coactivator interaction inhibitors. , 2012, Journal of medicinal chemistry.

[58]  Albertinka J Murk,et al.  Detection of thyroid hormone receptor disruptors by a novel stable in vitro reporter gene assay. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.